Effects of<i>Lactobacillus plantarum</i>CCFM0236 on hyperglycaemia and insulin resistance in high-fat and streptozotocin-induced type 2 diabetic mice

Li, Xiangfei; Wang, Na; Yin, Baoshu; Fang, Dongdong; Jiang, Tian; Fang, Shuguang; Zhao, Jianxin; Zhang, Hao; Wang, Gang; Chen, Wei

doi:10.1111/jam.13276

Cited by 83 publications

(52 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, in the present study, living strain was selected to feed mice. Results showed that L. acidophilus KLDS1.0901 treatment could significantly decrease food intake and FBG level and increase BW ( Figure 3A), which is consistent with other studies (Li et al, 2016). HbA1c, which is a clinical diagnostic parameter for diabetes, reflects the average plasma glucose concentration over a period of time.…”

Section: Discussionsupporting

confidence: 89%

Screening for Potential Novel Probiotics With Dipeptidyl Peptidase IV-Inhibiting Activity for Type 2 Diabetes Attenuation in vitro and in vivo

Yan

Yue

et al. 2020

Front. Microbiol.

View full text Add to dashboard Cite

Diabetes has become the second most severe disease to human health. Probiotics are important for maintaining gastrointestinal homeostasis and energy balance and have been demonstrated to play a positive role in the prevention and treatment of metabolic syndromes, such as obesity, inflammation, dyslipidemia, and hyperglycemia. The objective of this study was to screen potential antidiabetic strains in vitro and evaluate its effects in vivo. For the in vitro section, dipeptidyl peptidase IV (DPP-IV) inhibitory and antioxidant activities of 14 candidate Lactobacillus spp. strains were tested. Then hydrophobicity and acid and bile salt tolerance assays were determined. The most promising in vitro strain was further evaluated for its antidiabetic properties in vivo using type 2 diabetes mice induced by high-fat diet and intraperitoneal injection of streptozotocin (STZ). The reference strain for this study was Lactobacillus rhamnosus GG. Results showed that cell-free excretory supernatants and cell-free extracts of Lactobacillus acidophilus KLDS1.0901 had better DPP-IV inhibitory activity, antioxidative activities, and biological characteristics than other strains. At the end of the treatment, we found that L. acidophilus KLDS1.0901 administration decreased the levels of fasting blood glucose (FBG), glycosylated hemoglobin, insulin in serum and AUC glucose , and increased the level of glucagon-like peptide 1 in serum compared with diabetic mice (p < 0.05). Moreover, L. acidophilus KLDS1.0901 supplementation increased the activities of superoxide dismutase, glutathione peroxidase, the level of glutathione, and reduced the level of malondialdehyde in serum. These results indicated that L. acidophilus KLDS1.0901 could be used as a potential antidiabetic strain; its application as food supplement and drug ingredient is thus recommended.

show abstract

Section: Discussionsupporting

confidence: 89%

Screening for Potential Novel Probiotics With Dipeptidyl Peptidase IV-Inhibiting Activity for Type 2 Diabetes Attenuation in vitro and in vivo

Yan

Yue

et al. 2020

Front. Microbiol.

View full text Add to dashboard Cite

show abstract

“… 29 - 33 Moreover, several strains of L. plantarum species have been reported to improve the glycemic control in obese and diabetic patients, likely via their carbohydrate-utilizing genes. 34 , 35 Studies also indicate that administration of Bifidobacterium animalis, B. breve , and B. longum led to amelioration of glucose intolerance. 28 , 36 - 38 While results of individual studies have been quite variable, a recent meta-analysis has shown that these probiotics improve glycemic control and significantly decrease the risk of gestational diabetes mellitus in pregnant women.…”

Section: Probiotics In Diabetesmentioning

confidence: 99%

Considering gut microbiota in treatment of type 2 diabetes mellitus

2020

View full text Add to dashboard Cite

Advances in the understanding of the pathogenesis of type 2 diabetes mellitus (T2D) have revealed a role for gut microbiota dysbiosis in driving this disease. This suggests the possibility that approaches to restore a healthy host-microbiota relationship might be a means of ameliorating T2D. Indeed, recent studies indicate that many currently used treatments for T2D are reported to impact gut microbiota composition. Such changes in gut microbiota may mediate and/or reflect the efficacy of these interventions. This article outlines the rationale for considering the microbiota as a central determent of development of T2D and, moreover, reviews evidence that impacting microbiota might be germane to amelioration of T2D, both in terms of understanding mechanisms that mediate efficacy of exiting T2D therapies and in developing novel treatments for this disorder. ARTICLE HISTORY

show abstract

“…Accumulating evidence indicates that supplementation with specific probiotics in dietary interventions could affect the host metabolism and modulate the glucose homeostasis in an animal model and human studies (Holmes et al, 2012;Cano et al, 2013;Yadav et al, 2013;Cheng et al, 2015;Aoki et al, 2017). Some species within the Lactobacillus demonstrated anti-obesity (Karimi et al, 2015;Li et al, 2016) or anti-diabetic (Honda et al, 2012;Li et al, 2016) effects in animal models or humans.…”

Section: Introductionmentioning

confidence: 99%

Investigating the Mechanistic Differences of Obesity-Inducing Lactobacillus kefiranofaciens M1 and Anti-obesity Lactobacillus mali APS1 by Microbolomics and Metabolomics

Lin

Chen

et al. 2020

Front. Microbiol.

View full text Add to dashboard Cite

Many studies have investigated the anti-obesity effects of probiotics in animal models and humans. However, few studies have focused on the mechanisms of obesity-inducing probiotics. In a previous study, we demonstrated that specific bacterial strains isolated from kefir, Lactobacillus kefirnofaciens M1 and Lactobacillus mali APS1, possess obesity and anti-obesity effects, respectively, in high-fat diet (HFD)-induced obese mice. Thus, in the present study, we systematically investigated whether APS1 and M1 affect energy homeostasis and lipid metabolism in HFD-induced obese mice and how this might be achieved. We observed that the M1/APS1 intervention influenced fat accumulation by regulating adipogenesis and inflammation-related marker expression both in vitro and in a HFD induced C57BL/6J mice model. We also observed putative links between key taxa and possible metabolic processes of the gut microbiota. Notably, families Christensenellaceae and S24_7 were negatively correlated with body weight gain through increase in the essential esterized carnitine for energy expenditure. These results suggest the importance of specific probiotic interventions affecting leanness and obesity of subjects under a HFD, which are operated by modulating the tripartite relationship among the host, microbiota, and metabolites.

show abstract

Effects ofLactobacillus plantarumCCFM0236 on hyperglycaemia and insulin resistance in high-fat and streptozotocin-induced type 2 diabetic mice

Abstract: The method of α-glucosidase inhibitory activity could be effectively used to screen potential hypoglycaemic products and Lact. plantarum CCFM0236 might be a promising therapeutic agent for ameliorating type 2 diabetes.

Cited by 83 publications

References 32 publications

Screening for Potential Novel Probiotics With Dipeptidyl Peptidase IV-Inhibiting Activity for Type 2 Diabetes Attenuation in vitro and in vivo

Screening for Potential Novel Probiotics With Dipeptidyl Peptidase IV-Inhibiting Activity for Type 2 Diabetes Attenuation in vitro and in vivo

Considering gut microbiota in treatment of type 2 diabetes mellitus

Investigating the Mechanistic Differences of Obesity-Inducing Lactobacillus kefiranofaciens M1 and Anti-obesity Lactobacillus mali APS1 by Microbolomics and Metabolomics

Contact Info

Product

Resources

About